Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Key Terms

phase 1 medical

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

cns medical

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

u.s. securities and exchange commission regulatory

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR^® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website.

The third‑party article incorrectly claimed that Panna Sharma has stepped down as President and Chief Executive Officer of Lantern. This claim is false, entirely without basis, and appears designed to mislead investors. No such communication has been issued by the Company or its Board of Directors.

Mr. Sharma continues to serve as President, Chief Executive Officer, and a Director of Lantern, and remains fully engaged in leading the Company’s strategy, operations, and portfolio of AI‑driven oncology programs. He has no intention to step down from his roles with Lantern and he has not been requested to do so. As previously announced on March 23, 2026, Mr. Sharma will lead Lantern’s upcoming webcast to discuss fourth quarter and fiscal year 2025 operating and financial results on Monday, March 30, 2026, at 4:30 p.m. Eastern Time.

Neither Lantern nor its Board of Directors has approved or planned any CEO change. Any report suggesting otherwise is without merit.

Donald Jeff Keyser, Chairman of Lantern’s Board of Directors, stated: “The Board has full confidence in Panna Sharma’s leadership. Under his direction, Lantern continues to advance a robust clinical pipeline, including the recently cleared IND for Starlight Therapeutics’ planned Phase 1 pediatric CNS cancer trial of STAR-001 and the continued expansion of the Company’s AI‑driven drug development capabilities. We are disturbed by what appears to be a deliberate third‑party attempt to mislead investors and the market, and will pursue immediate corrective actions.”

Lantern cautions investors and other stakeholders to be vigilant against potential third‑party attempts to manipulate Lantern’s stock price through the dissemination of false or misleading information. Investors are encouraged to rely solely on Lantern’s official communications, including filings with the U.S. Securities and Exchange Commission and press releases available on the Company’s investor relations website.

The Company is actively investigating the origin and dissemination of today’s fabricated third‑party article, including any coordinated trading activity surrounding its publication. Lantern intends to pursue all available legal remedies and is considering referring this matter to the appropriate regulatory authorities.

Details for Q4 and Fiscal Year 2025 Webcast

As previously disclosed, Lantern will host a webcast to discuss its fourth quarter and fiscal year 2025 operating and financial results on Monday, March 30, 2026, at 4:30 p.m. Eastern Time. Mr. Sharma will lead the discussion and management intends to review results for the period ended December 31, 2025, and provide updates on key clinical programs and the continued evolution of the RADR^® AI platform.

Additional details, including webcast access information and a replay of the webcast, will be available on the Events & Presentations section of Lantern’s investor relations website.

About Lantern Pharma

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical‑stage biopharmaceutical company using its proprietary RADR^® artificial intelligence and machine learning platform to transform the cost, pace, and outcomes of oncology drug development. Lantern’s RADR^® platform analyzes extensive genomic and drug response data to identify biomarkers that predict patient response, enabling more efficient and targeted clinical trials. For more information, visit www.lanternpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260327821422/en/

Investor Relations Contact:
Lantern Pharma Inc.
ir@lanternpharma.com

Source: Lantern Pharma Inc.